Publications by authors named "P A Labrune"

Background: Aarskog-Scott syndrome (AAS) is a rare condition with multiple congenital anomalies, caused by hemizygote variants in the gene. Its description was based mostly on old case reports, in whom a molecular diagnosis was not always available, or on small series. The aim of this study was to better delineate the phenotype and the natural history of AAS and to provide clues for the diagnosis and the management of the patients.

View Article and Find Full Text PDF

Background: Hypoglycaemia is the primary manifestation of all the hepatic types of glycogen storage disease (GSD). In 2008, Glycosade, an extended-release waxy maize cornstarch, was reported as an alternative to uncooked cornstarch (UCCS) which could prolong the duration of fasting in the GSD population. To date, there has been minimal published experience in (a) young children, (b) the ketotic forms of GSD, and (c) with daytime dosing.

View Article and Find Full Text PDF

Purpose: The functionality of many cellular proteins depends on cofactors; yet, they have only been implicated in a minority of Mendelian diseases. Here, we describe the first 2 inherited disorders of the cytosolic iron-sulfur protein assembly system.

Methods: Genetic testing via genome sequencing was applied to identify the underlying disease cause in 3 patients with microcephaly, congenital brain malformations, progressive developmental and neurologic impairments, recurrent infections, and a fatal outcome.

View Article and Find Full Text PDF
Article Synopsis
  • - The study focused on patients with Crigler-Najjar syndrome, a condition characterized by the lack of the enzyme UGT1A1, leading to high bilirubin levels that can cause serious health issues, with liver transplantation being the only definitive treatment.
  • - Researchers tested an intravenous gene therapy using an adeno-associated virus to deliver UGT1A1 and observed safety and efficacy in five patients, with variable doses administered; no serious side effects were reported, though some patients experienced mild adverse reactions.
  • - The results showed that while patients receiving the lower dose did not achieve the desired bilirubin levels, those on the higher dose successfully reduced their bilirubin levels below the treatment threshold, suggesting potential benefits of the gene therapy
View Article and Find Full Text PDF